Search research articles
Contact Us
Filters
Showing results (1-10 of 165) with videos related to
Page
of 17
Sort By:
Msphere
|
March 28, 2020
mSphere of Influence: Understanding Virus-Host Interactions Requires a Multifaceted Approach
Rory D de Vries
Signal Transduction and Targeted Therapy
|
October 7, 2020
SARS-CoV-2-specific T-cells in unexposed humans: presence of cross-reactive memory cells does not equal protective immunity
Rory D de Vries
The Lancet. Infectious Diseases
|
December 23, 2023
Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants
Sander Herfst, Rory D de Vries
Human Vaccines & Immunotherapeutics
|
July 26, 2016
Viral vector-based influenza vaccines
Rory D de Vries, Guus F Rimmelzwaan
The Lancet. Infectious Diseases
|
September 8, 2022
Evaluating novel COVID-19 vaccines in the current chapter of the pandemic
Corine H GeurtsvanKessel, Rory D de Vries
Expert Review of Vaccines
|
August 24, 2012
Evaluating measles vaccines: can we assess cellular immunity?
Rory D de Vries, Rik L de Swart
Cell Host & Microbe
|
January 12, 2023
Antibodies face the challenge against human respiratory syncytial virus
Rory D de Vries, Rik L de Swart
Vaccines
|
July 26, 2018
Avian Influenza A Virus Pandemic Preparedness and Vaccine Development
Rory D de Vries, Sander Herfst, Mathilde Richard
Plos Pathogens
|
December 19, 2014
Measles immune suppression: functional impairment or numbers game?
Rory D de Vries, Rik L de Swart
The Lancet. Infectious Diseases
|
October 26, 2024
Steps towards licensure of self-amplifying RNA vaccines
Maarten F Wilbrink, Sander Herfst, Rory D de Vries
Page
of 17
Search research articles
Search
Showing results (1-10 of 165) with videos related to
Sort By:
Page
of 17
Msphere
|
March 28, 2020
mSphere of Influence: Understanding Virus-Host Interactions Requires a Multifaceted Approach
Rory D de Vries
Signal Transduction and Targeted Therapy
|
October 7, 2020
SARS-CoV-2-specific T-cells in unexposed humans: presence of cross-reactive memory cells does not equal protective immunity
Rory D de Vries
The Lancet. Infectious Diseases
|
December 23, 2023
Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants
Sander Herfst, Rory D de Vries
Human Vaccines & Immunotherapeutics
|
July 26, 2016
Viral vector-based influenza vaccines
Rory D de Vries, Guus F Rimmelzwaan
The Lancet. Infectious Diseases
|
September 8, 2022
Evaluating novel COVID-19 vaccines in the current chapter of the pandemic
Corine H GeurtsvanKessel, Rory D de Vries
Expert Review of Vaccines
|
August 24, 2012
Evaluating measles vaccines: can we assess cellular immunity?
Rory D de Vries, Rik L de Swart
Cell Host & Microbe
|
January 12, 2023
Antibodies face the challenge against human respiratory syncytial virus
Rory D de Vries, Rik L de Swart
Vaccines
|
July 26, 2018
Avian Influenza A Virus Pandemic Preparedness and Vaccine Development
Rory D de Vries, Sander Herfst, Mathilde Richard
Plos Pathogens
|
December 19, 2014
Measles immune suppression: functional impairment or numbers game?
Rory D de Vries, Rik L de Swart
The Lancet. Infectious Diseases
|
October 26, 2024
Steps towards licensure of self-amplifying RNA vaccines
Maarten F Wilbrink, Sander Herfst, Rory D de Vries
Page
of 17